Insights from 2023 EHA® Annual Meeting

 

Insights from 2023 EHA® Annual Meeting
Avatar

EHA® 2023 Insights: "4-Year Follow-Up From the Randomized Phase 2 VISION/HO141 Trial - Time-Limited Venetoclax & Ibrutinib for Patients With R/R CLL Who Have Undetectable MRD"

By Insights from 2023 EHA® Annual Meeting FEATURING Arnon Kater
By Insights from 2023 EHA® Annual Meeting FEATURING Arnon Kater
82 views
June 14, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

15:43
Incyte

Importance of Early Management of Patients with Myelofibrosis (MF)

Feat. P. Bose, R. Rampal

Featured Video

07:44
Incyte

Optimizing the Management of Patients with Polycythemia Vera (PV)

Feat. P. Bose, R. Rampal
Leukemia
10:42

Updated Data for Ziftomenib in Adults With NPM1-Mutated R/R AML

Insights from 2023 EHA® Annual Meeting

A. Fathi

241 views
16:16

Experts Discuss Key Updates in CLL From EHA and iCML

Insights from 2023 EHA® Annual Meeting

S. O'Brien, C. Coombs

446 views
06:28

EHA® 2023 Insights: "Venetoclax + Obinutuzumab for Previously Untrea…

Insights from 2023 EHA® Annual Meeting

O. Al-Sawaf

670 views
07:51

EHA® 2023 Insights: "4-Year Follow-Up From the Randomized Phase 2 VI…

Insights from 2023 EHA® Annual Meeting

A. Kater

82 views